<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21216" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Epidermolysis Bullosa Acquisita</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Xiao </surname>
            <given-names>Anny</given-names>
          </name>
          <aff>Western University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sathe</surname>
            <given-names>Nishad C.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tsuchiya</surname>
            <given-names>Arline</given-names>
          </name>
          <aff>University of California, Irvine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anny Xiao declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nishad Sathe declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Arline Tsuchiya declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>29</day>
          <month>10</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21216.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Epidermolysis bullosa acquisita (EBA) is a rare, chronic autoimmune blistering disease that affects both the skin and mucous membranes. This condition arises due to autoantibodies targeting type VII collagen&#x02014;a crucial component of anchoring fibrils within the dermal-epidermal junction. Although EBA can manifest in various phenotypes clinically, the classical mechanobullous and inflammatory forms are the most common presentations. This activity offers insights into the underlying pathogenesis of EBA, involving the production of autoantibodies targeting type VII collagen, which lead to epidermal detachment and the distinctive clinical features observed in EBA. This activity comprehensively reviews the epidemiology, diagnostic approaches, differential diagnosis, current treatment options, and challenges clinicians face in managing EBA. This course assists interprofessional healthcare team members enhance their competence to make well-informed decisions when caring for patients with EBA.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the clinical manifestations and symptoms of epidermolysis bullosa acquisita to facilitate early diagnosis.</p></list-item><list-item><p>Implement evidence-based treatment strategies and appropriate diagnostic tests to confirm the diagnosis of epidermolysis bullosa acquisita and guide treatment decisions.</p></list-item><list-item><p>Apply the principles of wound care and infection prevention specific to epidermolysis bullosa acquisita to minimize skin trauma and reduce the risk of secondary infections.</p></list-item><list-item><p>Coordinate and facilitate referrals to clinicians, including ophthalmologists, otolaryngologists, dentists, and gastroenterologists, when mucosal involvement is suspected, ensuring holistic patient care and early detection of complications.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21216&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21216">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21216.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Epidermolysis bullosa acquisita (EBA) is a rare, chronic autoimmune blistering disease that impacts both the skin and mucous membranes.&#x000a0;This condition arises due to autoantibodies targeting type VII collagen&#x02014;a crucial component of anchoring fibrils within the dermal-epidermal junction (DEJ).<xref ref-type="bibr" rid="article-21216.r1">[1]</xref>&#x000a0;These anchoring fibrils&#x000a0;are responsible for attaching the epidermis to the underlying dermis. When autoantibodies bind to type VII collagen, they cause the detachment of the epidermis, leading to skin fragility, blisters formation, erosions, scaring, milia formation, and nail loss.<xref ref-type="bibr" rid="article-21216.r2">[2]</xref>&#x000a0;</p>
        <p>Although EBA can manifest in various phenotypes clinically, the classical mechanobullous and inflammatory forms are the most common presentations.<xref ref-type="bibr" rid="article-21216.r3">[3]</xref> Classic mechanobullous EBA resembles dystrophic epidermolysis bullosa (EB), with bullae and erosions developing at sites of trauma. However, it is noteworthy that EBA is a distinct bullous disorder primarily affecting adults, whereas EB is more commonly found in children. Both conditions share a common name due to their presumed similar clinical features.<xref ref-type="bibr" rid="article-21216.r4">[4]</xref><xref ref-type="bibr" rid="article-21216.r5">[5]</xref></p>
        <p>Conversely, the inflammatory forms of EBA present clinical manifestations similar to those found in other autoimmune blistering disorders, including bullous pemphigoid (BP), mucous membrane pemphigoid (MMP), IgA bullous dermatosis, and Brunsting-Perry pemphigoid.</p>
        <p>Furthermore, EBA has been reported in association with various systemic diseases, including inflammatory bowel disease (IBD), thyroiditis, rheumatoid arthritis, hepatitis C infection, and diabetes mellitus.<xref ref-type="bibr" rid="article-21216.r6">[6]</xref></p>
      </sec>
      <sec id="article-21216.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>EBA is characterized by the presence of tissue-bound and circulating immunoglobulin (Ig)-G (gG) autoantibodies that target type VII collagen within the lamina densa and sublamina densa of the basement membrane zone (BMZ).<xref ref-type="bibr" rid="article-21216.r7">[7]</xref>&#x000a0;Type IV collagen is&#x000a0;a major component of anchoring fibrils&#x02014;a crucial structural component connecting the papillary dermis to the lamina densa. This connection plays a pivotal role in upholding the integrity of the epidermal BMZ.<xref ref-type="bibr" rid="article-21216.r8">[8]</xref>&#x000a0;</p>
        <p>The autoantibodies in EBA have been identified as specifically targeting the NC1 domain of type VII collagen located within the lamina densa.<xref ref-type="bibr" rid="article-21216.r9">[9]</xref>&#x000a0;Experimental mouse models and in vitro studies of EBA have demonstrated that autoantibodies targeting type VII collagen can induce dermal-epidermal separation.<xref ref-type="bibr" rid="article-21216.r10">[10]</xref> These antibodies may also directly disrupt the assembly of type VII collagen into anchoring fibrils or hinder its interactions with other matrix proteins, such as laminin 332, fibronectin, or type IV collagen.<xref ref-type="bibr" rid="article-21216.r2">[2]</xref><xref ref-type="bibr" rid="article-21216.r11">[11]</xref> These disruptions can result in the detachment of the epidermis, leading to the skin fragility and blister formation observed in EBA.</p>
        <p>Specific human leukocyte antigen (HLA) class II alleles are more prevalent in specific populations with EBA. For instance,&#x000a0;a higher frequency of HLA-DRB1*13 has been reported in Korean patients&#x000a0;<xref ref-type="bibr" rid="article-21216.r12">[12]</xref>, whereas HLA-DRB1*15:03 has been found in higher frequencies among African-American patients.<xref ref-type="bibr" rid="article-21216.r13">[13]</xref>&#x000a0;These data suggest that the expression of specific HLA alleles may influence the susceptibility to developing EBA. However, further research is necessary on this topic, as the available data have been derived from studies involving small groups of EBA patients.</p>
      </sec>
      <sec id="article-21216.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>EBA is regarded as one of the rarest subepidermal bullous diseases in Western Europe, with an estimated annual incidence ranging from 0.2 to 0.5 cases per million people.<xref ref-type="bibr" rid="article-21216.r14">[14]</xref>&#x000a0;The prevalence&#x000a0;appears to&#x000a0;be higher in&#x000a0;Korean&#x000a0;and African-American populations.<xref ref-type="bibr" rid="article-21216.r15">[15]</xref> Although EBA can manifest in both pediatric and adult patients, it is comparatively less common in children and predominantly afflicts adults. Gender does not appear to be a predisposing factor. Although EBA can manifest at any age, the average onset of EBA occurs between the fourth and fifth decades of life.<xref ref-type="bibr" rid="article-21216.r16">[16]</xref>&#x000a0;</p>
        <p>A comprehensive meta-analysis conducted in 2018, which included 1159 EBA cases, revealed that the median age was 50 for all patients with EBA. Pediatric patients&#x000a0;accounted&#x000a0;for 4.6% of reported cases, whereas those aged 65 or older accounted for 11.3%. Notably,&#x000a0;the age range in individuals of reported EBA cases has been reported to extend from&#x000a0;1 to 94.&#x000a0;</p>
        <p>Approximately 9.6% of EBA cases were identified to be associated with chronic inflammatory diseases. The most frequently reported associations included IBD, thyroiditis, and rheumatoid arthritis.<xref ref-type="bibr" rid="article-21216.r17">[17]</xref> Although the evidence supporting the connection between EBA and IBD is increasing, additional research is needed to establish the relationship between these 2 conditions.<xref ref-type="bibr" rid="article-21216.r18">[18]</xref><xref ref-type="bibr" rid="article-21216.r19">[19]</xref></p>
      </sec>
      <sec id="article-21216.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The exact cause of EBA&#x000a0;remains uncertain, but current evidence suggests a link to the production of antibodies against type VII collagen. This collagen type is a critical component of anchoring fibrils, essential for preserving the integrity of the DEJ.<xref ref-type="bibr" rid="article-21216.r20">[20]</xref> Type VII collagen is a homotrimer composed of repeat Gly-X-Y chains, surrounded by globular NC1 and NC2 domains at its amino and carboxy termini. In EBA, the NC1 domain is believed to be the primary antigen targeted by the autoimmune response.<xref ref-type="bibr" rid="article-21216.r21">[21]</xref>&#x000a0;</p>
        <p>The evidence for the involvement of type VII collagen in EBA is supported by various observations, including the presence of type VII collagen antibodies in histopathological examinations and the serum of affected patients. In addition, this presence correlates with the severity of the disease.<xref ref-type="bibr" rid="article-21216.r22">[22]</xref><xref ref-type="bibr" rid="article-21216.r23">[23]</xref><xref ref-type="bibr" rid="article-21216.r24">[24]</xref>&#x000a0;Moreover, similarities between EBA and&#x000a0;other bullous diseases, such as bullous lupus erythematosus (LE), which share a similar pathogenesis involving type VII collagen, provide additional support for its role in EBA pathophysiology.<xref ref-type="bibr" rid="article-21216.r25">[25]</xref>&#x000a0;</p>
        <p>Animal studies have&#x000a0;also provided&#x000a0;evidence regarding the pathogenicity of type VII collagen in EBA.<xref ref-type="bibr" rid="article-21216.r24">[24]</xref><xref ref-type="bibr" rid="article-21216.r26">[26]</xref><xref ref-type="bibr" rid="article-21216.r27">[27]</xref>&#x000a0;However, the exact mechanisms underlying&#x000a0;the formation&#x000a0;of these autoantibodies and their specific role in blister formation remain incompletely understood.&#x000a0;</p>
        <p>Current theories suggest that exposure to the neoantigen in the NC1 domain of type VII collagen, often related to trauma, can lead to antibody production, potentially compromising the adherence between the dermis and epidermis.<xref ref-type="bibr" rid="article-21216.r28">[28]</xref><xref ref-type="bibr" rid="article-21216.r29">[29]</xref><xref ref-type="bibr" rid="article-21216.r30">[30]</xref> However, further research is required to establish a more comprehensive understanding of the complete pathogenesis of this disease.</p>
      </sec>
      <sec id="article-21216.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Diagnosing EBA through histopathology can pose challenges due to its similarity and overlap with other bullous diseases. During hematoxylin and eosin (H&#x00026;E) staining analysis, EBA typically displays distinctive features such as subepidermal vesiculation, milia formation, and, in later lesions, dermal fibrosis due to scarring. In addition, fibrin deposition may be observed, potentially accompanied by neutrophils along the base of the vesiculation.<xref ref-type="bibr" rid="article-21216.r31">[31]</xref><xref ref-type="bibr" rid="article-21216.r32">[32]</xref><xref ref-type="bibr" rid="article-21216.r33">[33]</xref>&#x000a0;However, these features can remain somewhat indistinct in the context of blistering diseases, offering fewer distinctive characteristics when compared to conditions such as BP and linear IgA bullous dermatosis (LABD).<xref ref-type="bibr" rid="article-21216.r25">[25]</xref>&#x000a0;Therefore, to establish a definitive diagnosis of EBA, additional testing with techniques such as direct immunofluorescence (DIF), indirect immunofluorescence (IIF), or immunoelectron microscopy (IEM), which is considered the gold standard, may be required.<xref ref-type="bibr" rid="article-21216.r34">[34]</xref>&#x000a0;</p>
        <p>In DIF, a distinctive feature in EBA is the linear deposition of IgG and C3 at the DEJ. DIF is preferred over indirect immunofluorescence (IIF) because the latter may not contain sufficient antibodies in the patient's serum for accurate diagnosis.<xref ref-type="bibr" rid="article-21216.r35">[35]</xref><xref ref-type="bibr" rid="article-21216.r36">[36]</xref>&#x000a0;Another useful diagnostic tool is the salt-split skin examination, which can be conducted using either 1 M sodium chloride or 20 mM EDTA. This test reveals that the deposition of immune complexes is on the&#x000a0;floor (dermal side) rather than the roof (epidermal side), as observed in BP or bullous LE. As a result, EBA&#x000a0;exhibits a classic u-serrated pattern, in contrast to the n-serrated pattern observed in other bullous diseases.<xref ref-type="bibr" rid="article-21216.r20">[20]</xref><xref ref-type="bibr" rid="article-21216.r37">[37]</xref>&#x000a0;</p>
        <p>In addition to these established methods, newer testing options may involve immunoelectron or transmission electron&#x000a0;microscopy and enzyme-linked immunosorbent assay (ELISA), which can reveal the presence of neutrophils surrounding the affected area.<xref ref-type="bibr" rid="article-21216.r2">[2]</xref></p>
      </sec>
      <sec id="article-21216.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>EBA can manifest with various clinical phenotypes, and the classic presentation involves a noninflammatory mechanobullous disease characterized by skin fragility, tense blisters, erosions, scarring, milia formation, and postinflammatory dyspigmentation. These findings are localized to trauma-prone sites and&#x000a0;extensor surfaces, including the elbows, knees, dorsal hands, and feet.<xref ref-type="bibr" rid="article-21216.r17">[17]</xref>&#x000a0;Progressive acral involvement may be&#x000a0;disfiguring, resembling dystrophic EB with pseudosyndactyly, mitten deformity of digits, and nail dystrophy. In some cases, scalp involvement can lead to nonhealing erosions with scarring alopecia.<xref ref-type="bibr" rid="article-21216.r2">[2]</xref>&#x000a0;</p>
        <p>The&#x000a0;inflammatory variants&#x000a0;of EBA&#x000a0;resemble other autoimmune bullous dermatoses and include BP-like EBA, MMP-like EBA, LABD-like EBA, and Brunsting-Perry cicatricial pemphigoid&#x02013;like EBA.<xref ref-type="bibr" rid="article-21216.r17">[17]</xref> Classic noninflammatory EBA and BP-like EBA are the most frequently observed presentations among these variants.<xref ref-type="bibr" rid="article-21216.r8">[8]</xref>&#x000a0;BP-like EBA is characterized by widespread pruritic tense vesicles and bullae on an erythematous base, typically affecting the trunk, intertriginous areas, and extremities. Around 50% of cases may include the oral mucosa, leading to erosions or intact vesicles inside the mouth. Unlike classic noninflammatory EBA, lesions in BP-like EBA tend to heal without forming milia or scars.<xref ref-type="bibr" rid="article-21216.r38">[38]</xref>&#x000a0;</p>
        <p>MMP-like EBA is&#x000a0;distinguished by&#x000a0;its&#x000a0;primary involvement of mucous membranes, with lesions and scarring most commonly observed in the&#x000a0;mouth, upper esophagus, conjunctivae, anus, and vagina.<xref ref-type="bibr" rid="article-21216.r39">[39]</xref>&#x000a0;In some cases, severe&#x000a0;ocular involvement has also been reported, which can lead to&#x000a0;blindness.<xref ref-type="bibr" rid="article-21216.r40">[40]</xref>&#x000a0;</p>
        <p>Tense vesicles, blisters, and urticarial plaques arranged in an annular or polycyclic pattern characterize LABD-like EBA. This variant of EBA can also affect mucous membranes and skin lesions.</p>
        <p>Brunsting-Perry cicatricial pemphigoid&#x02013;like EBA presents as a vesiculobullous eruption primarily localized&#x000a0;to the head and neck region, with little to no involvement of mucous membranes. Involvement of the scalp results in scarring alopecia.<xref ref-type="bibr" rid="article-21216.r41">[41]</xref>&#x000a0;</p>
        <p>Patients&#x000a0;with EBA may present with a single described subtype or exhibit a combination of&#x000a0;2 subtypes simultaneously. Reports of clinical features shifting from one particular variant to another exist during the course of the disease.<xref ref-type="bibr" rid="article-21216.r11">[11]</xref></p>
      </sec>
      <sec id="article-21216.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnosing EBA can be challenging due to various inflammatory variants that closely resemble other blistering diseases, both in terms of clinical presentation and histological features.&#x000a0;</p>
        <p>In histological examination, a skin biopsy obtained from lesional EBA skin typically reveals features such as papillary edema and vacuolar degeneration along the DEJ&#x000a0;in early lesions. In later lesions, a subepidermal blister becomes apparent, and the degree of inflammatory infiltrate varies based on the clinical variant of EBA.<xref ref-type="bibr" rid="article-21216.r11">[11]</xref>&#x000a0;</p>
        <p>The classic EBA presentation is pauci-inflammatory, displaying a limited neutrophilic inflammatory infiltrate in the papillary dermis. In contrast, BP-like EBA features a dermal inflammatory infiltrate composed of neutrophils, lymphocytes, monocytes, and eosinophils, resulting in a histological appearance closely resembling BP.&#x000a0;</p>
        <p>In suspected cases of EBA, performing a perilesional biopsy for DIF microscopy is advisable. DIF typically reveals linear deposits of IgG along the epidermal BMZ. Less commonly,&#x000a0;linear deposits of C3, IgA, or IgM may&#x000a0;also be detected.<xref ref-type="bibr" rid="article-21216.r11">[11]</xref> A "u-serrated" immunodeposition pattern at the BMZ aids in distinguishing EBA from other subepidermal blistering disorders, which typically exhibit an "n-serrated" pattern.<xref ref-type="bibr" rid="article-21216.r42">[42]</xref>&#x000a0;</p>
        <p>Furthermore, salt-split skin immunofluorescence preparations can reveal immune deposits on the dermal side of the cleavage. This is in contrast to the pattern observed in BP, where deposits are located on the epidermal side of the separation.<xref ref-type="bibr" rid="article-21216.r11">[11]</xref></p>
        <p>IIF may detect circulating autoantibodies to the BMZ in patients with EBA. Approximately 50% of EBA patients have detectable anti-BMZ IgG antibodies in their serum, resulting in a linear fluorescent band along the DEJ.</p>
        <p>Furthermore, performing IIF on salt-split skin can provide additional insights. The patient's serum is applied to artificially split skin in this test. If EBA-specific autoantibodies are present, they will bind to the dermal side of the artificial blister, indicating a positive result for EBA.</p>
        <p>Transmission electron microscopy of the DEJ reveals cleavage in the sublamina densa zone, a decreased number of anchoring fibrils emerging&#x000a0;from the lamina densa,&#x000a0;and the presence of an amorphous, electron-dense material beneath the lamina densa in EBA skin. This material corresponds&#x000a0;to the IgG deposits bound to the anchoring fibrils.<xref ref-type="bibr" rid="article-21216.r43">[43]</xref></p>
        <p>IEM is the traditional "gold standard" for diagnosing&#x000a0;EBA. This technique can reveal immune deposits specifically localized to anchoring fibrils within the sublamina densa, setting it apart from other subepidermal blistering disorders where immune deposits in the hemidesmosome area (as in BP) or lamina lucida (as in MMP).<xref ref-type="bibr" rid="article-21216.r44">[44]</xref></p>
        <p>Western blot analysis of serum from patients with EBA reveals the binding of circulating autoantibodies to a 290-kDa protein and, occasionally, a 145-kDa protein. These proteins correspond to the alpha chain of type VII collagen and its NC1 domain.<xref ref-type="bibr" rid="article-21216.r22">[22]</xref></p>
        <p>ELISA is a rapid and effective test with a high specificity of more than 96%. This test utilizes recombinant NC1 and NC2 domains of type VII collagen purified from human cells to detect EBA autoantibodies targeting all potential antigenic epitopes within NC1 and NC2. This method can also quantify levels of autoantibodies that correlate with disease severity.</p>
        <p>Previous authors have established the diagnostic criteria for EBA. These criteria include the presence of a bullous disorder within the defined clinical spectrum of EBA, the absence of a family history of bullous disease, histological evidence of a subepidermal blister, DIF examination of perilesional skin revealing IgG deposits within the DEJ, and IEM of perilesional skin confirming the localization of IgG deposits within the lower lamina densa or sublamina densa of the DEJ. Alternative tests, such as IIF, salt-split skin, ELISA, and Western blotting technique, may be conducted instead of IEM.<xref ref-type="bibr" rid="article-21216.r11">[11]</xref></p>
      </sec>
      <sec id="article-21216.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Managing EBA can be difficult because some patients may not respond positively to treatment. Supportive therapy should be a fundamental component of EBA treatment for all affected individuals. This involves ensuring proper wound care and maintaining optimal nutrition, which are paramount in minimizing the risk of complications.</p>
        <p>Patients should receive counseling on strategies to prevent skin trauma, such as limiting exposure to harsh soaps and hot water, refraining from vigorous skin rubbing, and avoiding prolonged sun exposure.<xref ref-type="bibr" rid="article-21216.r11">[11]</xref>&#x000a0;Furthermore, educating patients&#x000a0;on recognizing signs of secondary skin infections and when to seek medical care to prevent further complications is crucial.</p>
        <p>Regular monitoring of patients is essential to detect the development of mucosal lesions. Periodic comprehensive reviews of their systems and physical exams are necessary for identifying changes or disease progression. Due to its rarity, pharmacological treatment data for EBA primarily relies on anecdotal reports.<xref ref-type="bibr" rid="article-21216.r40">[40]</xref> However, some therapeutic approaches have shown promising results in managing&#x000a0;the&#x000a0;various variants of EBA.</p>
        <p>High doses of colchicine have demonstrated effectiveness in patients with classic mechanobullous EBA and its inflammatory variants.<xref ref-type="bibr" rid="article-21216.r45">[45]</xref> Although the mechanism of action remains unclear, colchicine is believed to reduce the production of antibodies and inhibit antigen presentation to T cells.<xref ref-type="bibr" rid="article-21216.r46">[46]</xref>&#x000a0;</p>
        <p>For BP-like EBA and other inflammatory variants, systemic corticosteroids and immunosuppressive medications, including azathioprine, cyclophosphamide, cyclosporine, methotrexate, and mycophenolate mofetil, may prove effective.<xref ref-type="bibr" rid="article-21216.r47">[47]</xref> Dapsone has been reported to offer some benefits, especially in EBA patients with neutrophilic dermal infiltrates. In cases of childhood EBA, studies have recommended a combination of dapsone and prednisolone.<xref ref-type="bibr" rid="article-21216.r40">[40]</xref>&#x000a0;In severe cases of EBA refractory to conventional immunosuppressive therapy, case reports have indicated successful use of rituximab and intravenous immunoglobulins (IVIG).<xref ref-type="bibr" rid="article-21216.r48">[48]</xref></p>
      </sec>
      <sec id="article-21216.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnosis for&#x000a0;EBA includes other subepidermal blistering disorders, such as dystrophic EB, BP, MMP, porphyria cutanea tarda (PCT), pseudoporphyria, IgA bullous dermatosis, Brunsting-Perry pemphigoid, and bullous LE.</p>
        <p>Dominant dystrophic EB may bear a clinical resemblance to the mechanobullous type of EBA. However, it can be differentiated by a positive family history of a bullous disorder, onset at birth, and negative DIF findings.</p>
        <p>BP and MMP can exhibit clinical similarities to the inflammatory variants of EBA. However, they can be differentiated by the presence of an n-serrated DIF immunodeposition pattern, as seen in IgA bullous dermatosis. Other diagnostic tests, including IIF with salt-split skin substrate, ELISA, Western immunoblotting, or IEM, can assist in ruling out other autoimmune bullous diseases.</p>
        <p>PCT classically involves the hands but&#x000a0;can be distinguished from EBA by performing specific porphyrin studies. PCT is associated with elevated levels of porphyrins in urine and stool, which are not seen in EBA. Likewise, pseudoporphyria may resemble EBA, but patients with pseudoporphyria would also have a history of chronic kidney disease, renal dialysis, or the use of specific drugs, such as nonsteroidal anti-inflammatory drugs, furosemide, antibiotics, and retinoids.<xref ref-type="bibr" rid="article-21216.r49">[49]</xref>&#x000a0;</p>
        <p>Bullous LE can seldom manifest as a mechanobullous eruption, displaying features such as tense blisters, milia, and scarring. Nevertheless, histological examination of bullous LE reveals subepidermal bullae with a predominantly neutrophilic infiltrate and dermal papillary microabscesses that resemble dermatitis herpetiformis.<xref ref-type="bibr" rid="article-21216.r2">[2]</xref> Bullous LE would also typically show significant improvement with initiating systemic LE treatment, whereas EBA typically has a poor response to treatment.<xref ref-type="bibr" rid="article-21216.r50">[50]</xref></p>
      </sec>
      <sec id="article-21216.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>EBA is a chronic blistering disease characterized by recurring periods of exacerbations and remissions. The prognosis of the condition depends on the severity at the time of diagnosis and the response to treatment. In a retrospective analysis conducted by Kim et al, the median time to remission after treatment with immunosuppressive agents was approximately 9 months. After 1 year, approximately 33% of patients achieved complete remission, and this percentage increased to 45% by 6 years.<xref ref-type="bibr" rid="article-21216.r40">[40]</xref>&#x000a0;Long-term maintenance therapy is&#x000a0;often&#x000a0;necessary to&#x000a0;sustain disease control.<xref ref-type="bibr" rid="article-21216.r51">[51]</xref>&#x000a0;</p>
        <p>Mortality directly related to EBA is rare, and patients who&#x000a0;receive adequate&#x000a0;treatment and proper management can expect an average life span. The prognosis and response to treatment may be more favorable in children than adults.<xref ref-type="bibr" rid="article-21216.r52">[52]</xref></p>
      </sec>
      <sec id="article-21216.s12" sec-type="Complications">
        <title>Complications</title>
        <p>EBA is a challenging condition to treat and can lead to significant morbidity<xref ref-type="bibr" rid="article-21216.r23">[23]</xref>. Severe exacerbations of EBA may heal with rapid scarring, causing joint contractures, syndactyly, and nail loss.<xref ref-type="bibr" rid="article-21216.r53">[53]</xref> EBA can affect the ocular, gastrointestinal, and respiratory mucosa, potentially causing significant functional impairment.<xref ref-type="bibr" rid="article-21216.r54">[54]</xref> Complications of mucosal involvement include ankyloglossia, periodontal disease, symblepharon formation, nasal synechiae, esophageal strictures, and supraglottic stenosis.<xref ref-type="bibr" rid="article-21216.r55">[55]</xref> Mucosal disease in EBA can often remain subclinical, resulting in delayed diagnosis and an increased risk of serious complications.<xref ref-type="bibr" rid="article-21216.r55">[55]</xref></p>
        <p>Immunosuppressive medications to treat EBA, such as systemic corticosteroids, dapsone, cyclosporine, or colchicine, can result in significant morbidity, especially when prolonged treatment is required for disease control.</p>
      </sec>
      <sec id="article-21216.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>EBA causes the skin to be fragile and forms blisters easily, especially at&#x000a0;trauma sites. Patients should be educated on the preventative measures for skin trauma.<xref ref-type="bibr" rid="article-21216.r32">[32]</xref>&#x000a0;To prevent skin trauma, it is recommended that patients with EBA be instructed to follow the below-mentioned steps.</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients should avoid vigorous rubbing or excessive skin washing because these actions can lead to blister formation.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients must refrain from using adhesive bandages or tape on the skin, which can cause additional trauma.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients can minimize friction and pressure on the skin by wearing loose-fitting clothing and comfortable shoes.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients can reduce blister formation by keeping their skin cool and avoiding prolonged exposure to heat and humidity.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients should avoid using shower water warmer than body temperature because hot water can harm fragile skin.&#x000a0;</p>
          </list-item>
        </list>
        <p>Patients&#x000a0;with EBA should receive guidance on properly caring&#x000a0;for eroded blisters.<xref ref-type="bibr" rid="article-21216.r56">[56]</xref>&#x000a0;To minimize the risk of developing a secondary bacterial infection, it is recommended to apply antibacterial ointment over skin erosions. When dressing wounds, individuals should opt for nonadhesive dressings and consider using gauze wraps for loose and gentle coverage while avoiding adhesives that may cause further trauma to delicate skin. Healthcare providers should instruct patients on recognizing signs of secondary skin infection and when to seek medical care for nonhealing or worsening wounds. Physicians&#x000a0;may also need to provide nutritional support for optimal wound healing and monitor patients for dietary deficiencies.<xref ref-type="bibr" rid="article-21216.r57">[57]</xref></p>
      </sec>
      <sec id="article-21216.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing the complex and varied clinical presentations of EBA, as well as its potential complications, requires a multidisciplinary team of healthcare providers consisting of dermatologists, wound care specialists, nutritionists, occupational therapists, and physical therapists to treat EBA in patients.</p>
        <p>Regular monitoring for the development or progression of mucosal involvement is essential for patients. If mucosal lesions are present or suspected, patients should seek specialized evaluation and treatment from ophthalmologists, otolaryngologists, dentists, and gastroenterologists.</p>
        <p>A collaborative healthcare team approach ensures comprehensive care for the patient's condition, thereby improving outcomes and a more favorable prognosis. Timely diagnosis and treatment are essential for effectively managing the disease and preventing further complications. Educating patients and their families about the condition, symptom management, and adherence to the prescribed treatment plan is also essential to address the treatment effectively.</p>
      </sec>
      <sec id="article-21216.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21216&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21216">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/epidermolysis-bullosa-acquisita/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=21216">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21216/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21216">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21216.s16">
        <title>References</title>
        <ref id="article-21216.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haeger</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Kridin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pieper</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Griewahn</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nimmerjahn</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zillikens</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>K&#x000f6;nig</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ludwig</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Hundt</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic effects of Fc gamma RIV inhibition are mediated by selectively blocking immune complex-induced neutrophil activation in epidermolysis bullosa acquisita.</article-title>
            <source>Front Immunol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>938306</fpage>
            <pub-id pub-id-type="pmid">36311755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Prakash</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Woodley</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <article-title>Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen.</article-title>
            <source>Autoimmunity</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>91</fpage>
            <page-range>91-101</page-range>
            <pub-id pub-id-type="pmid">21955050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kridin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kneiber</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kowalski</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Valdebran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Amber</surname>
                <given-names>KT</given-names>
              </name>
            </person-group>
            <article-title>Epidermolysis bullosa acquisita: A comprehensive review.</article-title>
            <source>Autoimmun Rev</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>8</issue>
            <fpage>786</fpage>
            <page-range>786-795</page-range>
            <pub-id pub-id-type="pmid">31181325</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guerra</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Condorelli</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Fortugno</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Calabresi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pedicelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Di Zenzo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Castiglia</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Epidermolysis Bullosa (EB) Acquisita in an Adult Patient with Previously Unrecognized Mild Dystrophic EB and Biallelic COL7A1 Mutations.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2018</year>
            <month>Apr</month>
            <day>16</day>
            <volume>98</volume>
            <issue>4</issue>
            <fpage>411</fpage>
            <page-range>411-415</page-range>
            <pub-id pub-id-type="pmid">29182795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goyal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Balachandran</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bhogal</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zillikens</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Childhood Epidermolysis Bullosa Acquisita: Confirmation of Diagnosis by Skin Deficient in Type VII Collagen, Enzyme-linked Immunosorbent Assay, and Immunoblotting.</article-title>
            <source>Indian J Dermatol</source>
            <year>2016</year>
            <season>May-Jun</season>
            <volume>61</volume>
            <issue>3</issue>
            <fpage>329</fpage>
            <page-range>329-32</page-range>
            <pub-id pub-id-type="pmid">27293257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iranzo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Herrero-Gonz&#x000e1;lez</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Mascar&#x000f3;-Galy</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Su&#x000e1;rez-Fern&#x000e1;ndez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Espa&#x000f1;a</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Epidermolysis bullosa acquisita: a retrospective analysis of 12 patients evaluated in four tertiary hospitals in Spain.</article-title>
            <source>Br J Dermatol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>171</volume>
            <issue>5</issue>
            <fpage>1022</fpage>
            <page-range>1022-30</page-range>
            <pub-id pub-id-type="pmid">24890437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wo&#x0017a;niak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kowalewski</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Alterations of basement membrane zone in autoimmune subepidermal bullous diseases.</article-title>
            <source>J Dermatol Sci</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>3</issue>
            <fpage>169</fpage>
            <page-range>169-75</page-range>
            <pub-id pub-id-type="pmid">15990279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Epidermolysis bullosa acquisita.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>10</issue>
            <fpage>1204</fpage>
            <page-range>1204-13</page-range>
            <pub-id pub-id-type="pmid">23368767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barreiro-Capurro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mascar&#x000f3;-Galy</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Iranzo</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Retrospective study of the clinical, histologic, and immunologic features of epidermolysis bullosa acquisita in 9 patients.</article-title>
            <source>Actas Dermosifiliogr</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>104</volume>
            <issue>10</issue>
            <fpage>904</fpage>
            <page-range>904-14</page-range>
            <pub-id pub-id-type="pmid">23895729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sitaru</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Experimental models of epidermolysis bullosa acquisita.</article-title>
            <source>Exp Dermatol</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>16</volume>
            <issue>6</issue>
            <fpage>520</fpage>
            <page-range>520-31</page-range>
            <pub-id pub-id-type="pmid">17518993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Woodley</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Epidermolysis bullosa acquisita.</article-title>
            <source>Clin Dermatol</source>
            <year>2012</year>
            <season>Jan-Feb</season>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-9</page-range>
            <pub-id pub-id-type="pmid">22137228</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Distribution of HLA class II alleles in Korean patients with epidermolysis bullosa acquisita.</article-title>
            <source>Dermatology</source>
            <year>1996</year>
            <volume>193</volume>
            <issue>4</issue>
            <fpage>328</fpage>
            <page-range>328-9</page-range>
            <pub-id pub-id-type="pmid">8993959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zumelzu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Le Roux-Villet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Loiseau</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Busson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aucouturier</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pendaries</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Li&#x000e8;vre</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pascal</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Brette</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Doan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Charron</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Caux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Laroche</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Petit</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Prost-Squarcioni</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Black patients of African descent and HLA-DRB1*15:03 frequency overrepresented in epidermolysis bullosa acquisita.</article-title>
            <source>J Invest Dermatol</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>131</volume>
            <issue>12</issue>
            <fpage>2386</fpage>
            <page-range>2386-93</page-range>
            <pub-id pub-id-type="pmid">21833018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vaillant</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Labeille</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bedane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arbeille</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Denoeux</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Lorette</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bonnetblanc</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Prost</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group.</article-title>
            <source>Arch Dermatol</source>
            <year>1995</year>
            <month>Jan</month>
            <volume>131</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-52</page-range>
            <pub-id pub-id-type="pmid">7826096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Prevalences of subacute cutaneous lupus erythematosus and Epidermolysis bullosa acquisita among Korean/Oriental populations.</article-title>
            <source>Dermatology</source>
            <year>1998</year>
            <volume>197</volume>
            <issue>2</issue>
            <fpage>187</fpage>
            <pub-id pub-id-type="pmid">9732174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arpey</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Elewski</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Moritz</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Gammon</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Childhood epidermolysis bullosa acquisita. Report of three cases and review of literature.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1991</year>
            <month>May</month>
            <volume>24</volume>
            <issue>5 Pt 1</issue>
            <fpage>706</fpage>
            <page-range>706-14</page-range>
            <pub-id pub-id-type="pmid">1869641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iwata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Vorobyev</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koga</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Recke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zillikens</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Prost-Squarcioni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ludwig</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2018</year>
            <month>Sep</month>
            <day>04</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>153</fpage>
            <pub-id pub-id-type="pmid">30180870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bezzio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Della Corte</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vernero</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Luna</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Manes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Saibeni</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations.</article-title>
            <source>Therap Adv Gastroenterol</source>
            <year>2022</year>
            <volume>15</volume>
            <fpage>17562848221115312</fpage>
            <pub-id pub-id-type="pmid">35924080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antonelli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bassotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tramontana</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hansel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stingeni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ardizzone</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Genovese</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marzano</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Maconi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Dermatological Manifestations in Inflammatory Bowel Diseases.</article-title>
            <source>J Clin Med</source>
            <year>2021</year>
            <month>Jan</month>
            <day>19</day>
            <volume>10</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">33477990</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gribaleva</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>van der Molen</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Horvath</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Allenova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Diercks</surname>
                <given-names>GFH</given-names>
              </name>
              <name>
                <surname>Pas</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Subepidermal type VII collagen speckles as an additional clue for diagnosing epidermolysis bullosa acquisita by salt-split skin serum analysis.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2022</year>
            <month>May</month>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>e384</fpage>
            <page-range>e384-e386</page-range>
            <pub-id pub-id-type="pmid">35030274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woodley</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Cogan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mosallaei</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yim</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Characterization of mutant type VII collagens underlying the inversa subtype of recessive dystrophic epidermolysis bullosa.</article-title>
            <source>J Dermatol Sci</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>104</volume>
            <issue>2</issue>
            <fpage>104</fpage>
            <page-range>104-111</page-range>
            <pub-id pub-id-type="pmid">34674926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woodley</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Briggaman</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>O'Keefe</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Inman</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Queen</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Gammon</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita.</article-title>
            <source>N Engl J Med</source>
            <year>1984</year>
            <month>Apr</month>
            <day>19</day>
            <volume>310</volume>
            <issue>16</issue>
            <fpage>1007</fpage>
            <page-range>1007-13</page-range>
            <pub-id pub-id-type="pmid">6369131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bohelay</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Alexandre</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Le Roux-Villet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sitbon</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Doan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Soued</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Shourick</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rousset</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mellottee</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Li&#x000e8;vre</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zumelzu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Grootenboer-Mignot</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gabison</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Caux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Prost-Squarcioni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Musette</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients.</article-title>
            <source>Front Immunol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>915205</fpage>
            <pub-id pub-id-type="pmid">35844526</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vicari</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Haeberle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bolduan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ramcke</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Vorobyev</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Goletz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iwata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ludwig</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Enk</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Hadaschik</surname>
                <given-names>EN</given-names>
              </name>
            </person-group>
            <article-title>Pathogenic Autoantibody Derived from Regulatory T Cell&#x02012;Deficient Scurfy Mice Targets Type VII Collagen and Leads to Epidermolysis Bullosa Acquisita&#x02012;Like Blistering Disease.</article-title>
            <source>J Invest Dermatol</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>142</volume>
            <issue>3 Pt B</issue>
            <fpage>980</fpage>
            <page-range>980-984.e4</page-range>
            <pub-id pub-id-type="pmid">34678154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Montagnon</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Tolkachjov</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Murrell</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Camilleri</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Lehman</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Subepithelial autoimmune blistering dermatoses: Clinical features and diagnosis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>85</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-14</page-range>
            <pub-id pub-id-type="pmid">33684496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edwards</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Diercks</surname>
                <given-names>GFH</given-names>
              </name>
              <name>
                <surname>Seelen</surname>
                <given-names>MAJ</given-names>
              </name>
              <name>
                <surname>Horvath</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>van Doorn</surname>
                <given-names>MBA</given-names>
              </name>
              <name>
                <surname>Damman</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Complement Activation in Autoimmune Bullous Dermatoses: A Comprehensive Review.</article-title>
            <source>Front Immunol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>1477</fpage>
            <pub-id pub-id-type="pmid">31293600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niebuhr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bieber</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Banczyk</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maass</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ludwig</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zillikens</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Westermann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kalies</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Epidermal Damage Induces Th1 Polarization and Defines the Site of Inflammation in Murine Epidermolysis Bullosa Acquisita.</article-title>
            <source>J Invest Dermatol</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>140</volume>
            <issue>9</issue>
            <fpage>1713</fpage>
            <page-range>1713-1722.e9</page-range>
            <pub-id pub-id-type="pmid">32057838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Collin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zillikens</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>EndoS reduces the pathogenicity of anti-mCOL7 IgG through reduced binding of immune complexes to neutrophils.</article-title>
            <source>PLoS One</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>e85317</fpage>
            <pub-id pub-id-type="pmid">24504190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marzano</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Cozzani</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fanoni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>De Pit&#x000e0;</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Vassallo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Berti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Parodi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Crosti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cugno</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and disease severity assessment of epidermolysis bullosa acquisita by ELISA for anti-type VII collagen autoantibodies: an Italian multicentre study.</article-title>
            <source>Br J Dermatol</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>168</volume>
            <issue>1</issue>
            <fpage>80</fpage>
            <page-range>80-4</page-range>
            <pub-id pub-id-type="pmid">22913489</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Human skin basement membrane in health and in autoimmune diseases.</article-title>
            <source>Front Biosci</source>
            <year>1997</year>
            <month>Jul</month>
            <day>15</day>
            <volume>2</volume>
            <fpage>d343</fpage>
            <page-range>d343-52</page-range>
            <pub-id pub-id-type="pmid">9232815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prosty</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guirguis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chergui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Afif</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Netchiporouk</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Epidermolysis bullosa acquisita treated with ustekinumab: A case report.</article-title>
            <source>SAGE Open Med Case Rep</source>
            <year>2022</year>
            <volume>10</volume>
            <fpage>2050313X221091600</fpage>
            <pub-id pub-id-type="pmid">35449527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miyamoto</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gordilho</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Santi</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Porro</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Epidermolysis bullosa acquisita.</article-title>
            <source>An Bras Dermatol</source>
            <year>2022</year>
            <season>Jul-Aug</season>
            <volume>97</volume>
            <issue>4</issue>
            <fpage>409</fpage>
            <page-range>409-423</page-range>
            <pub-id pub-id-type="pmid">35701269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uchida</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oiso</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Koga</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Okahashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Matsuda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kawada</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Refractory bullous pemphigoid leaving numerous milia during recovery.</article-title>
            <source>J Dermatol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>41</volume>
            <issue>11</issue>
            <fpage>1003</fpage>
            <page-range>1003-5</page-range>
            <pub-id pub-id-type="pmid">25346302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prost-Squarcioni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Caux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jonkman</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Vassileva</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Iranzo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Daneshpazhooh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Terra</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fairley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hertl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lehman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Marinovic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Patsatsi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zillikens</surname>
                <given-names>D</given-names>
              </name>
              <collab>International Bullous Diseases Group</collab>
              <name>
                <surname>Werth</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Woodley</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Murrell</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita.</article-title>
            <source>Br J Dermatol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>179</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-41</page-range>
            <pub-id pub-id-type="pmid">29165796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holtsche</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>van Beek</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Di Zenzo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zillikens</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Prost-Squarcioni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Titeux</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hovnanian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Goletz</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of Epidermolysis Bullosa Acquisita: Multicentre Comparison of Different Assays for Serum Anti-type VII Collagen Reactivity.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2021</year>
            <month>Mar</month>
            <day>23</day>
            <volume>101</volume>
            <issue>3</issue>
            <fpage>adv00420</fpage>
            <pub-id pub-id-type="pmid">33686442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Witte</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zillikens</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of Autoimmune Blistering Diseases.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2018</year>
            <volume>5</volume>
            <fpage>296</fpage>
            <pub-id pub-id-type="pmid">30450358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arora</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shetty</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Serration pattern analysis as a practical adjunct tool for categorization of subepidermal autoimmune blistering diseases.</article-title>
            <source>Indian J Dermatol Venereol Leprol</source>
            <year>2021</year>
            <season>Nov-Dec</season>
            <volume>87</volume>
            <issue>6</issue>
            <fpage>778</fpage>
            <page-range>778-786</page-range>
            <pub-id pub-id-type="pmid">34491679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cobos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Beasley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brinster</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Femia</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Epidermolysis bullosa acquisita.</article-title>
            <source>Dermatol Online J</source>
            <year>2017</year>
            <month>Dec</month>
            <day>15</day>
            <volume>23</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">29447655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stewart</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Woodley</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Briggaman</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Epidermolysis bullosa acquisita and associated symptomatic esophageal webs.</article-title>
            <source>Arch Dermatol</source>
            <year>1991</year>
            <month>Mar</month>
            <volume>127</volume>
            <issue>3</issue>
            <fpage>373</fpage>
            <page-range>373-7</page-range>
            <pub-id pub-id-type="pmid">1998368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Epidermolysis bullosa acquisita: a retrospective clinical analysis of 30 cases.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2011</year>
            <month>May</month>
            <volume>91</volume>
            <issue>3</issue>
            <fpage>307</fpage>
            <page-range>307-12</page-range>
            <pub-id pub-id-type="pmid">21394418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asfour</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chong</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Groves</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Epidermolysis Bullosa Acquisita (Brunsting-Perry Pemphigoid Variant) Localized to the Face and Diagnosed With Antigen Identification Using Skin Deficient in Type VII Collagen.</article-title>
            <source>Am J Dermatopathol</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>39</volume>
            <issue>7</issue>
            <fpage>e90</fpage>
            <page-range>e90-e96</page-range>
            <pub-id pub-id-type="pmid">28452792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vodegel</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Jonkman</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Pas</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases.</article-title>
            <source>Br J Dermatol</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>151</volume>
            <issue>1</issue>
            <fpage>112</fpage>
            <page-range>112-8</page-range>
            <pub-id pub-id-type="pmid">15270879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richter</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>McNutt</surname>
                <given-names>NS</given-names>
              </name>
            </person-group>
            <article-title>The spectrum of epidermolysis bullosa acquisita.</article-title>
            <source>Arch Dermatol</source>
            <year>1979</year>
            <month>Nov</month>
            <volume>115</volume>
            <issue>11</issue>
            <fpage>1325</fpage>
            <page-range>1325-8</page-range>
            <pub-id pub-id-type="pmid">389167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nieboer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Boorsma</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Woerdeman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kalsbeek</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Epidermolysis bullosa acquisita. Immunofluorescence, electron microscopic and immunoelectron microscopic studies in four patients.</article-title>
            <source>Br J Dermatol</source>
            <year>1980</year>
            <month>Apr</month>
            <volume>102</volume>
            <issue>4</issue>
            <fpage>383</fpage>
            <page-range>383-92</page-range>
            <pub-id pub-id-type="pmid">6992836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cunningham</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Kirchmann</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Woodley</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Colchicine for epidermolysis bullosa acquisita.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1996</year>
            <month>May</month>
            <volume>34</volume>
            <issue>5 Pt 1</issue>
            <fpage>781</fpage>
            <page-range>781-4</page-range>
            <pub-id pub-id-type="pmid">8632074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ishii</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hamada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dainichi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Karashima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yasumoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zillikens</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Epidermolysis bullosa acquisita: what's new?</article-title>
            <source>J Dermatol</source>
            <year>2010</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>220</fpage>
            <page-range>220-30</page-range>
            <pub-id pub-id-type="pmid">20507385</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hallel-Halevy</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nadelman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Woodley</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <article-title>Epidermolysis bullosa acquisita: update and review.</article-title>
            <source>Clin Dermatol</source>
            <year>2001</year>
            <season>Nov-Dec</season>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>712</fpage>
            <page-range>712-8</page-range>
            <pub-id pub-id-type="pmid">11705680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crichlow</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Mortimer</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Harman</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita.</article-title>
            <source>Br J Dermatol</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>156</volume>
            <issue>1</issue>
            <fpage>194</fpage>
            <page-range>194-6</page-range>
            <pub-id pub-id-type="pmid">17199602</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Manders</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Pseudoporphyria.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2001</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>100</fpage>
            <page-range>100-8</page-range>
            <pub-id pub-id-type="pmid">11148469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Terra</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Jonkman</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Diercks</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Pas</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Low sensitivity of type VII collagen enzyme-linked immunosorbent assay in epidermolysis bullosa acquisita: serration pattern analysis on skin biopsy is required for diagnosis.</article-title>
            <source>Br J Dermatol</source>
            <year>2013</year>
            <month>Jul</month>
            <volume>169</volume>
            <issue>1</issue>
            <fpage>164</fpage>
            <page-range>164-7</page-range>
            <pub-id pub-id-type="pmid">23480491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koga</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Prost-Squarcioni</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Iwata</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jonkman</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Ludwig</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Bieber</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Epidermolysis Bullosa Acquisita: The 2019 Update.</article-title>
            <source>Front Med (Lausanne)</source>
            <year>2018</year>
            <volume>5</volume>
            <fpage>362</fpage>
            <pub-id pub-id-type="pmid">30687710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Callot-Mellot</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bodemer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Caux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bourgault-Villada</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fraitag</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goudi&#x000e9;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>de Prost</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Prost</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Epidermolysis bullosa acquisita in childhood.</article-title>
            <source>Arch Dermatol</source>
            <year>1997</year>
            <month>Sep</month>
            <volume>133</volume>
            <issue>9</issue>
            <fpage>1122</fpage>
            <page-range>1122-6</page-range>
            <pub-id pub-id-type="pmid">9301589</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Borradori</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Caldwell</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Briggaman</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Burr</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Gammon</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Yancey</surname>
                <given-names>KB</given-names>
              </name>
            </person-group>
            <article-title>Passive transfer of autoantibodies from a patient with mutilating epidermolysis bullosa acquisita induces specific alterations in the skin of neonatal mice.</article-title>
            <source>Arch Dermatol</source>
            <year>1995</year>
            <month>May</month>
            <volume>131</volume>
            <issue>5</issue>
            <fpage>590</fpage>
            <page-range>590-5</page-range>
            <pub-id pub-id-type="pmid">7741548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schauer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nystr&#x000f6;m</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kunz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>H&#x000fc;bner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Scholl</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Athanasiou</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Alter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Has</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kiritsi</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Case Report: Diagnostic and Therapeutic Challenges in Severe Mechanobullous Epidermolysis Bullosa Acquisita.</article-title>
            <source>Front Immunol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>883967</fpage>
            <pub-id pub-id-type="pmid">35464429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luke</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Darling</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Summers</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Yancey</surname>
                <given-names>KB</given-names>
              </name>
            </person-group>
            <article-title>Mucosal morbidity in patients with epidermolysis bullosa acquisita.</article-title>
            <source>Arch Dermatol</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>135</volume>
            <issue>8</issue>
            <fpage>954</fpage>
            <page-range>954-9</page-range>
            <pub-id pub-id-type="pmid">10456345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCuin</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Hanlon</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mutasim</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune bullous diseases: diagnosis and management.</article-title>
            <source>Dermatol Nurs</source>
            <year>2006</year>
            <month>Feb</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <page-range>20-5</page-range>
            <pub-id pub-id-type="pmid">16550892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21216.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pellicer</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Santiago</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alonso</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ant&#x000f3;n</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bosca</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Management of cutaneous disorders related to inflammatory bowel disease.</article-title>
            <source>Ann Gastroenterol</source>
            <year>2012</year>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-26</page-range>
            <pub-id pub-id-type="pmid">24713996</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
